Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

NCT ID: NCT00115141

Last Updated: 2007-02-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 88 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-04-30

Brief Summary

The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks.

A second purpose is to evaluate the safety of the drug.

Conditions

Warts

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Interventions

Resiquimod

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosis of common warts
• Two forms of birth control

Exclusion Criteria

• Pregnant or breast feeding
• Other types of warts, ie. plantar
• Currently participating in another clinical study
• Chronic viral hepatitis B or C

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Graceway Pharmaceuticals, LLC

INDUSTRY

Sponsor Role: lead

Other Identifiers

1513-RESI

Identifier Type: -

Identifier Source: org_study_id